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Background: The microscopic residual tumor at the bronchial margin after radical surgery (R1 resection) affects
prognosis negatively in non-small-cell lung cancer (NSCLC) patients. For patients with good performance status, a
potential cure still exists. Here, we report the outcomes of concurrent paclitaxel-based chemo-radiotherapy (CRT) for
NSCLC patients with microscopically positive bronchial margins or peribronchial infiltration.
Methods: A retrospective search in the clinical database was conducted in three hospitals. Patients were identified
and evaluated if treated with radiotherapy combined with paclitaxel-based chemotherapy. The objects analyzed
were local control time, progression-free survival (PFS), overall survival (OS), and treatment-related toxicity.
Results: Sixty-one patients with microscopic residual tumor at the bronchial stump following pulmonary lobectomy
were identified. Forty-six patients who had received concurrent paclitaxel-based CRT were analyzed. The median
follow-up was 40 months (range: 15.0–77.5 months). The 1-, 2- and 3-year survival rates were 97.8%, 60.9% and
36.9%, respectively. The local recurrences were recorded in 19.6% (9/46) patients. Median PFS and OS for the
evaluated cohort were 23.0 [95% confidence interval (CI): 21.3–24.7] and 32.0 (95% CI: 23.7–40.3) months,
respectively. The most common side effects were hematological toxicity (neutropenia, 93.5%; anemia, 89.1%; and
thrombocytopenia, 89.1%) and no treatment-related deaths. Grade ≥2 acute radiation-induced pneumonitis and
esophagitis were recorded in 43.5% (20/46) and 26.1% (12/46) patients, respectively. By univariate analysis, non-
squamous cell lung cancer was associated with a significantly longer survival time (45.1 vs 26.4 months, p = 0.013).
Conclusions: For NSCLC patients with post-surgical microscopic residual tumor at the bronchial stump, concurrent
paclitaxel-based chemo-radiotherapy achieved promising outcomes with accepted treatment-related toxicity.Background
Anatomic pulmonary lobectomy with radical lymph
node dissection is the primary treatment for operable
non-small-cell lung cancer (NSCLC) [1]. Complete re-
section of NSCLC should be confirmed pathologically
when all resection margins are free from tumor (R0 re-
section). The incidence of microscopic residual tumor at
the bronchial margin (R1 resection) is 4–5% (range: 1.2–* Correspondence: gongyouling@hotmail.com
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unless otherwise stated.17%) of all lung operations [2]. Although the classifica-
tion of an R1 resection at the bronchial margin is not
uniform in the literature, Wind et al. concluded that it
could be divided into submucosal residual disease, peri-
bronchial residual disease, and extrabronchial residual
disease [2]. Microscopic residual tumor might negatively
affect prognosis, with 1- and 5-year survival rates among
these patients between 20-50% and 0–20%, respectively
[2]. So far, there have been no randomized trials compar-
ing different treatment strategies in such patients.
Nevertheless, the panel of the National Comprehensive
Cancer Network (NCCN) still recommended that repeathis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Basic and clinical characteristics of the patients in
present study (n = 46)
Characteristics Number of patients (%)
Age (years)
Median (range) 57 (39–75)
Gender





Zhou et al. BMC Cancer  (2015) 15:36 Page 2 of 7resection or chemo-radiotherapy should be considered if
the patients have positive bronchial margins [1]. In such
patients, a potential for cure still exists.
Liewald et al. reported that in patients after R1 resec-
tion, reoperation might improve survival in Stage I (64
vs 21 months) and Stage II (38 vs 12 months) disease
[3]. Snijder et al. reported 28 patients with Stage I
NSCLC and microscopic residual tumor at the bronchial
margin [4]. The 5-year survival rate of the patients who
underwent reoperation was 40% as compared with 27%
in patients that did not. Therefore, reoperation in pa-
tients with Stage I and II NSCLC and R1 resection of
the bronchial resection margin is recommended [1,3-5].
Similarly, postoperative radiotherapy (PORT) is often
given in clinical practice if microscopic residual tumor is
present at the resection margin, based on the results of
several retrospective studies showing a reduction in the
local recurrence rates [6-8]. However, the value of PORT
is controversial and some studies have reported high
local recurrence rates following PORT in this specific
population [4,9]. Thus, the NCCN panel indicated that
CRT is an alternative strategy for Stage II or III disease
with bronchial positive margins [1].
In clinical practice, patients with NSCLC after a R1 re-
section at the bronchial margin may be considered as
potentially curable if their performance status is good.
Concurrent CRT consisting of cisplatin and etoposide,
paclitaxel and cisplatin (TP), and paclitaxel and carbo-
platin (TC) regimens has been used for salvage and de-
finitive treatment, according to the NCCN guidelines
[1].
In this study, we retrospectively evaluated the clinical
outcomes of patients treated with curative-intent CRT,
giving detailed information of the survival and related
side effects, with the intention of proving suitable treat-
ment for patients after R1 resection at the bronchial
margin.Squamous-cell carcinoma 28 (60.9)
Adenocarcinoma 14 (30.4)
Other types 4 (8.7)
T staging after surgeryb
T2/T3/T4 11 (23.9)/21 (45.7)/14 (30.4)
N staging after surgeryb
N0/N1/N2 10 (21.7)/22 (47.8)/14 (30.4)





Median (range) 40 (15.0-77.5)
a: Eastern Cooperative Oncology Group; b: Staging system, 6th edition,
American Joint Committee on Cancer, 2002.Methods
Patient data
R1 resection was defined as invasive microscopic re-
sidual tumor at the bronchial margin, or peribronchial
infiltration without any tumor lesion at the bronchial
stump area at baseline computed tomography (CT)
4 weeks after surgery. Between March 2007 and August
2012, 61 NSCLC patients received CRT for bronchial
positive margin at West China Hospital, Second People’s
Hospital of Sichuan, and Second Affiliated Hospital of
Anhui Medical University. Forty-six patients received
paclitaxel-based CRT. All of the patients had histologi-
cally proven NSCLC. This retrospective study was car-
ried out with the approval of the Ethics Committee of
West China Hospital, the Second People’s Hospital ofSichuan and the Second Affiliated Hospital of Anhui
Medical University.
The basic and clinical characteristics of the study
population are summarized in Table 1. The median age
of the patients was 57 years; most of them were male
and had an Eastern Cooperative Oncology Group
(ECOG) performance status score of 0–1. Twenty-eight
and fourteen patients had squamous cell carcinoma and
adenocarcinoma, respectively. The initial tumor stage
(Staging system, American Joint Committee on Cancer,
6th edition) [10] after surgery was Stage II (11; 23.9%),
Stage IIIa (29; 63.0%), and Stage IIIb (6; 13.1%). The me-




The regimens consisted of paclitaxel 175 mg/m2 plus
cisplatin 75 mg/m2 (TP regimen), paclitaxel 175 mg/m2
plus or carboplatin (AUC = 5) (TC regimen), or pacli-
taxel 175 mg/m2 plus oxaliplatin 135 mg/m2 (TO regi-
men) on Day 1 given every 3 weeks. The only adverse
effects were Grade ≥3 acute treatment-induced pneu-
monitis or esophagitis, and if prolonged, chemotherapy
Table 3 Treatment in present study (n = 46)




PTV volumea (cm3, median/range) 182.6/162.2-278.4
Irradiation dose for PTV2b (Gy, median/range) 60/50-70
Number of fractions (median/range) 30/25-35
Total lung V20 (%,median/range) 21/17-24
Mean lung dose (Gy,median/range) 11.7/10.3-12.8
Chemotherapy
Chemotherapy regimensc
Paclitaxel and Cisplatin 31 (67.4%)
Paclitaxel and Carboplatin 11 (23.9%)
Paclitaxel and Oxaliplatin 4 (8.7%)
Number of chemotherapy cycles (median/range) 3 (1–4)
Number of concurrent cycles (median/range) 2 (1–3)
a: Planning target volume; b: generated according to the GTV; c: all
chemotherapy regimens were delivered per three weeks.
Zhou et al. BMC Cancer  (2015) 15:36 Page 3 of 7was discontinued. Otherwise, the chemotherapy was sus-
pended until recovery and the drug dose was reduced by
25% in the subsequent cycle.
According to the NCCN guidelines [1], adjuvant
chemotherapy (including concurrent cycles with radio-
therapy) was delivered at a maximum of four cycles.
Radiotherapy
All patients underwent CT simulation. Gross tumor vol-
ume (GTV) was defined as the site of the bronchial posi-
tive margin (2 cm around the bronchial stump). As
described in Table 2, the clinical tumor volume (CTV)
enclosed the GTV with an 8-mm margin and the high-
risk draining lymph node stations followed the classifica-
tion by Mountain et al. [11]. For the planning target vol-
ume (PTV), a 10-mm margin was added isotropically to
the CTV (PTV1) and GTV (PTV2). The dose-volume
constraints for the lungs were set as follows: V20 < 22%
and mean lung dose <12 Gy. A maximum dose of 45 Gy
was allowed to the spinal cord (planning risk volume).
The patients received a conventional-fraction schedule.
The dose prescribed for PTV1 was 50 Gy and that for
PTV2 was at ≥60 Gy. Radiotherapy started at the latest
on the first day of the second chemotherapy cycle.
The details of the concurrent CRT are shown in
Table 3.
Treatment assessment
Local failure was defined as recurrence at the bronchial
stump and within the irradiated field. The regional fail-
ure was defined as lymph node recurrence outside the
irradiated field. Local control was defined as no recur-
rence in the local and regional fields. Progression was
defined as local recurrence or appearance of new lesions.
Follow-up evaluations were performed 4 weeks after
treatment, every 2–3 months for the first 2 years, and
every 6 months thereafter.
Toxicity was evaluated and graded according to the
National Cancer Institute Common Toxicity Criteria
version 3.0 [12]. A diagnosis of radiation-induced pneu-







10,7 and 4R 10, 7, 4R [irradiate 2R if 4R (+)]
Lower lobectomy 10 and 7 10, 7 [irradiate 8/9 if 8/9 (+)]
Left
Upper lobectomy 10, 7, 4 L and 5 10, 7, 4 L and 5 [irradiate 2 L
if 4 L (+)]
Lower lobectomy 10 and 7 10, 7 [irradiate 8/9 if 8/9 (+)]
a: Followed the lymph node classification [11]; b: clinical target volume.cough, shortness of breath and fever), with radiological
findings in the absence of any other likely cause.
Statistical methods
Statistical analyses were performed using SPSS version
17.0. Progression-free survival (PFS) was measured from
the date the treatment began to the date of disease pro-
gression, and overall survival (OS) was considered from
the start of treatment to the date of data analysis, or date
of loss from follow-up for patients alive, or date of death.
Patients without local recurrence or progression who
discontinued follow-up for any reason were censored on
the last day of tumor assessment. The rates of PFS and
OS were calculated using the Kaplan-Meier method.
Log-rank test and Cox’s proportional hazards regression
model were used for univariate survival analysis. Patient
age, sex, ECOG performance status, pathological type,
disease stage after surgery, chemotherapy regimen, and
radiation dose were included in univariate analysis.
Results
All patients received a radiation dose of ≥50 Gy (for
PTV1), and 78.3% (36/46) patients completed the
planned radiotherapy (for PTV2). The median radiation
dose delivered was 60 Gy, with a range of 50–70 Gy
(Table 2). Thirty-one, 11 and 4 patients received the TP,
TC and TO regimens, respectively, and 6.5% (3/46),
89.1% (41/46) and 4.3% (2/46) of patients received one,
two and three cycles of chemotherapy with concurrent
radiotherapy, respectively.
Follow-up studies continued until December 2013,
with no one lost. Only one patient was diagnosed with
Zhou et al. BMC Cancer  (2015) 15:36 Page 4 of 7brain metastasis at the first follow-up. Local and regional
failure was observed in four and two patients, respect-
ively. One patient was diagnosed with local and regional
failure. The local control rate was 84.8%. The 1-, 2- and
3-year survival rates were 97.8%, 60.9% and 36.9%, re-
spectively. Median PFS and OS for the evaluated cohort
were 23.0 months [95% confidence interval (CI): 21.3-
24.7 months) and 32.0 months (95% CI: 23.7-
40.3 months), respectively (Figure 1).
Treatment-related toxicity
All the patients were evaluated for treatment-related
toxicity (Table 4). The combination of chemotherapy (ei-
ther TP, TC or TO regimens) and radiotherapy proved
to be tolerable. The most common toxicity was neu-
tropenia (93.5%, 43/46). Grade 3 and 4 neutropenia was
observed in 16 (34.8%) and one (2.2%) patients, res-
pectively. Other major toxicities G1/2 included ane-
mia, thrombocytopenia and acute esophagitis. Grade 3
treatment-related acute pneumonitis was observed in
three (6.5%), nausea and vomiting in 8 (17.3%) pa-
tients. No grade 5 toxicity was recorded among any
patients.
Systemic treatment after disease progression
Twenty-seven patients (58.7%) were recorded with dis-
ease progression during follow-up. Local recurrence and
tumor metastasis were observed in nine (19.6%) and 18
(39.1%) patients, respectively. Most of them (92.6%) re-
ceived systemic treatment after disease progression, and
only two patients received palliative radiotherapy.
Among the patients with squamous-cell lung cancer,
eight patients had received the gemcitabine/platinum
regimen. Among the patients with non-squamous cell
lung cancer, five patients had received the pemetrexed/
platinum regimen and 5 patients had received tyrosine
kinase inhibitors (TKIs: erlotinib or gefitinib).Figure 1 Kaplan-Meier analysis of progression-free survival (a) and ovUnivariate survival analysis
Because of the small number of patients, only univariate
analysis was performed according to the basic and clin-
ical characteristics of the patients. The details are shown
in Table 5. Age, sex, ECOG performance status, disease
stage after surgery, chemotherapy regimen, and radiation
dose did not significantly affect survival time. Patho-
logical type (non-squamous cell lung cancer) was sig-
nificantly associated with improved OS (median: 45.1
months), compared with patients with squamous-cell lung
cancer (median OS: 26.4 months, p = 0.013) (Figure 2).
Discussion
To our knowledge, this is the first report of concurrent
CRT for post-surgical microscopic residual tumor at the
bronchial margin in patients with NSCLC. Paclitaxel-
based chemotherapy and concurrent radiotherapy
achieved a median OS of 32.0 months among those
NSCLC patients after R1 resection, with tolerable
treatment-related toxicity. Although this was a retro-
spective evaluation with a small sample, our data suggest
that selected NSCLC patients after R1 resection may
benefit from aggressive and curative-intent concurrent
CRT.
Reports from Liewald et al. and Snijder et al. show
that for Stage I and II NSCLC patients with positive
margins, repeat resection could improve OS [3,4] and is
recommended by NCCN [1] for Stage II patients. In the
present study, 11 patients (23.9%) with Stage II NSCLC
did not undergo repeat resection, but received CRT. As
recorded in our database, four patients refused reopera-
tion because of limited cardiopulmonary function, and
the others did not want a second operation. Among
these patients, the median survival time was 35.2 months,
which was similar to the reported data of repeat resec-
tion in Stage II cases by Liewald et al. (median OS:
38 months) [3].erall survival (b) in the present study.
Table 4 The treatment-related toxicities in present study (n = 46)
Toxicitiesa Toxicity grades, n (%)
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Hematological
Neutropenia 3 (6.5) 12 (26.1) 14 (30.4) 16 (34.8) 1 (2.2)
Anemia 5 (10.9) 25 (54.3) 16 (34.8) 0 0
Thrombocytopenia 5 (10.9) 21 (45.7) 20 (43.4) 0 0
Non-hematological
Nausea and vomiting 9 (19.6) 17 (37.0) 12 (26.1) 8 (17.3) 0
Acute esophagitis 6 (13.0) 28 (60.9) 12 (26.1) 0 0
Acute pneumonitis 8 (17.3) 18 (39.2) 17 (37.0) 3 (6.5) 0
a: According to the Common Toxicity Criteria for Adverse Events, version 3.0.
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for R2 resection or mediastinal recurrence, and the se-
quential CRT for R1 resection [1]. However, there is no
direct evidence of any disadvantage of concurrent set-
tings in NSCLC patients with R1 resection. Concurrent
chemoradiation improves the clinical outcomes of Stage
IIIA or IIIB disease [13-15]. In the present study, salvage
CRT was well-tolerated and toxicity was as expected
from thoracic CRT. The median OS was 32.0 months,
which is comparable to those data collected from pa-
tients with bronchial stump recurrence [16]. Recently,
Bar et al. reported the outcomes of CRT for loco-
regional recurrence of NSCLC after surgery, and the me-
dian survival after recurrence was 26.9 months [17].
Thus, for patients with good ECOG performance status
after R1 resection, concurrent CRT is still a treatment of
choice.Table 5 Prognostic factors by log-rank test and univariate su
Factors Group Nu




ECOGc performance status 0-1 41
2 4
Pathology Squamous-cell lung cancer 28
Non-squamous cell lung cancer 18
Staging after surgeryd II 11
III 35
Chemotherapy regimen TP 31
TC/TO 15
Irradiation dose ≧60 Gy 40
<60 Gy 16
a: Cox’s proportional hazards regression model; b: overall survival; c: Eastern CorporaIt should be mentioned that three patients (6.5%) de-
veloped acute grade 3 radiation pneumonitis after treat-
ment. Two patients had received right lower lobectomy
and one left lower lobectomy. The delivered dose was
60, 62 and 60 Gy respectively, and the chemotherapy
regimen was paclitaxel and cisplatin. They were diag-
nosed with Grade 3 radiation pneumonitis between 2
and 4 weeks after radiotherapy and finally recovered
after steroid therapy. The incidence of RP is somewhat
lower than the concurrent CRT for locally advanced
NSCLC. Among several parameters based on dose-
volume histograms, Vdose and mean lung dose (MLD)
are important predictive factors of acute radiation pneu-
monitis [18,19]. In definitive chemo-radiotherapy for
NSCLC, the NCCN panel suggests that a V20 value of
30-35% and MLD <20 Gy are thresholds for sympto-





















tive Oncology Group; d: According to the AJCC 6th staging system.
Figure 2 Kaplan-Meier analysis of overall survival in the
present study, according to the pathology type of the patients.
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situation. Uno et al. reported that in a 21-patient popu-
lation, three patients developed grade ≥2 radiation pneu-
monitis after concurrent CRT [20]. They found that
the V20 < 20%/MLD <10 Gy might be predictive factors
for grade ≥2 radiation pneumonitis in post-lobectomy
patients receiving definitive radiotherapy. In our prac-
tice, the lung constraints were set as V20 < 22% and
MLD <12 Gy. All these constraints need more studies
for validation.
In this study, the drug doses were modified in 19
(41.3%) patients during treatment. In addition, the gran-
ulocyte colony stimulating factor (G-CSF) is routinely
applied for secondary prophylaxis in our practice when
patients have grade 1 or 2 neutropenia in the preceding
cycle. In some situations, we use G-CSF prophylactically
among patients after chemotherapy to avoid any break
in radiotherapy. So, the rate of grade 4 neutropenia (1
patient, 2.2%) was lower than expected. No grade ≥3
acute esophagitis was observed in this study. To avoid
any break in radiotherapy as a consequence of grade 3
acute esophagitis, we usually prescribe a liquid combin-
ation (500 ml 0.9% physiological saline injection, 10 ml
1% lidocaine injection, and 10 mg dexamethasone mixed
with each other, 15 ml P.O three times per day) among
the patients with acute grade 2 esophagitis.
Another issue that should be discussed here is the tar-
get delineation. As all tumors are microscopic at the
bronchial margin, it was difficult to define the GTV.
Griess et al. [21] and Cotton [22] have reported that
even after resection, in which there is a macroscopictumor-free margin >2 cm, the incidence of R1 resection
was still around 6% among these resections. From the
report by Olszyna-Serementa et al., 80 patients with R1
resection have been analyzed [23]. They concluded that
the PORT results in a relatively better survival in these
patients. They also suggested that the elective nodal ir-
radiation was useful for local control in pN0–1 patients.
At present, the precise definition of GTV and CTV in
an R1-resection situation had not been concluded and
needs more clinical investigation.
By univariate survival analysis, we found that patho-
logical type (non-squamous cell lung cancer) was signifi-
cantly longer survival time, compared with patients with
squamous-cell lung cancer (45.1 vs 26.4 months, p =
0.013). This result differs from the studies of Ghiribelli
et al. [5] and Liewald et al. [3]. This may in part be ex-
plained by imbalances in the selection of subsequent
treatment regimens with respect to histological subtypes.
Currently, it is well known that several new anti-tumor
drugs (including pemetrexed and TKIs) could signifi-
cantly prolong the survival time among patients with
metastatic non-squamous cell lung cancer, since a series
of landmark trials has been published [24-27]. It might
be the reason that these patients survive longer than the
others in the present study.
Limitations of the present study should be mentioned.
First, the retrospective nature of the study and the small
number of the patients must be paid attention when inter-
preting the results. Second, the patients analyzed in this
study had good ECOG performance status (0 or 1). Some
patients could not tolerate the adjuvant CRT or chemo-
therapy alone, if their performance status was 2 or 3.
Conclusions
Concurrent paclitaxel-based chemo-radiotherapy is a
feasible treatment strategy for NSCLC patients after R1
resection, with as-expected treatment-related toxicity.
However, the most suitable chemotherapy regimen and
the optimal radiotherapy planning (target delineation
and normal tissue constraints) are not established and
require further investigation.
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